8.36
-0.18 (-2.11%)
| Previous Close | 8.54 |
| Volume | 675,827 |
| Price / Earnings (Forward) | 10.63 |
| Price / Sales | 8.54 |
| Price / Book | 1.55 |
| 52 Weeks Range |
| Profit Margin | -79.94% |
| Operating Margin (TTM) | -2,318.99% |
| Diluted EPS (TTM) | -2.05 |
| Quarterly Revenue Growth (YOY) | 5,556.00% |
| Total Debt/Equity (MRQ) | 2.33% |
| Current Ratio (MRQ) | 9.00 |
| Operating Cash Flow (TTM) | -130.36 M |
| Levered Free Cash Flow (TTM) | -35.38 M |
| Return on Assets (TTM) | -15.49% |
| Return on Equity (TTM) | -23.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Prothena Corporation plc | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 4.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 18.99% |
| % Held by Institutions | 74.34% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SCULLY WILLIAM P | 8.75 | - | 265,500 | 2,324,880 |
| Aggregate Net Quantity | 265,500 | |||
| Aggregate Net Value ($) | 2,324,880 | |||
| Aggregate Avg. Buy ($) | 8.75 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SCULLY WILLIAM P | 29 Sep 2026 | Buy (+) | 162,000 | 8.78 | 1,422,360 | |
| SCULLY WILLIAM P | 28 Sep 2026 | Buy (+) | 103,500 | 8.72 | 902,520 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |